FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer.
from "updates on food" - Google News https://ift.tt/2YpouFL
Wednesday 3 July 2019
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) - GlobeNewswire
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA) GlobeNewswire
from "updates on food" - Google News https://ift.tt/2YpouFL
from "updates on food" - Google News https://ift.tt/2YpouFL
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment